Related Experiment Videos
Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors
K Lampert1, U Machein, M R Machein
1Abteilung Neuropathologie, Medizinische Universitätsklinik, Universität Freiburg, Germany. lampert@nz11.ukl.uni-freiburg.de
Abstract:
In this study, we investigated the expression patterns of 15 matrix metalloproteinases (MMPs) and three tissue inhibitors of metalloproteinase in gliomas, medulloblastomas, and normal brain tissue. By Northern blot analysis we found increased levels of mRNAs encoding for gelatinase A, gelatinase B, two membrane-type MMPs (mt1- and mt2-MMP), and tissue inhibitors of metalloproteinase-1 in glioblastomas and medulloblastomas. We observed a significant increase of mt1-MMP, gelatinase A, gelatinase B, and tissue inhibitors of metalloproteinase-1 in glioblastomas as compared with low-grade astrocytomas, anaplastic astrocytomas, and normal brain. In medulloblastomas, the expression of mt1-MMP, mt2-MMP, and gelatinase A were also increased, but to a lesser extent than that observed in glioblastomas. These data were confirmed at the protein level by immunostaining analysis. Moreover, substrate gel electrophoresis showed that the activated forms of gelatinases A and B were present in glioblastomas and medulloblastomas. These results suggest that increased expression of mt1-MMP/gelatinase A is closely related to the malignant progression observed in gliomas. Furthermore, the present study demonstrates, to our knowledge for the first time, that medulloblastomas express high levels of MMP.
Insights
This study found increased matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinase-1 in aggressive brain tumors like glioblastomas and medulloblastomas, suggesting a role in tumor progression.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Biochemistry
Background:
- Gliomas and medulloblastomas are primary brain tumors with varying degrees of malignancy.
- Matrix metalloproteinases (MMPs) are enzymes involved in extracellular matrix degradation, implicated in tumor invasion and metastasis.
- Tissue inhibitors of metalloproteinases (TIMPs) regulate MMP activity.
Purpose of the Study:
- To investigate the expression patterns of 15 MMPs and 3 TIMPs in gliomas, medulloblastomas, and normal brain tissue.
- To correlate MMP and TIMP expression with tumor grade and malignant progression.
Main Methods:
- Northern blot analysis to quantify mRNA levels of MMPs and TIMPs.
- Immunohistochemistry to confirm protein expression.
- Substrate gel electrophoresis to detect activated MMP forms.
Main Results:
- Elevated mRNA levels of gelatinase A, gelatinase B, membrane-type MMPs (mt1-MMP, mt2-MMP), and TIMP-1 were observed in glioblastomas and medulloblastomas compared to normal brain tissue.
- Glioblastomas showed significantly higher expression of mt1-MMP, gelatinase A, gelatinase B, and TIMP-1 than lower-grade gliomas.
- Medulloblastomas exhibited increased expression of mt1-MMP, mt2-MMP, and gelatinase A, though less pronounced than in glioblastomas.
- Activated forms of gelatinase A and B were detected in glioblastomas and medulloblastomas.
- Protein-level expression was confirmed via immunostaining.
Conclusions:
- Increased expression of mt1-MMP and gelatinase A is strongly associated with the malignant progression of gliomas.
- Medulloblastomas demonstrate high levels of MMP expression, a novel finding.
- MMPs and TIMP-1 are potential biomarkers for brain tumor malignancy and progression.